Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAYLOR: Volrustomig in Solid Tumors with Mature TLS
2023-503451-94-00Phase 2Terminated
- Sponsor
- Institut Bergonié
- Start
- Oct 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of volrustomig in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), mesothelioma and 11 more (2 cohorts), sponsored by Institut Bergonié. Started Oct 2023; status: terminated.
02
Drugs
volrustomig
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)mesotheliomapancreatic cancer (PC)gastric cancer (GC)
Beyond the preview
Go deeper on 2023-503451-94-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503451-94-00.